Cocrystal Pharma Inc (COCP)
Cocrystal Pharma Inc. is a biotechnology company focused on discovering and developing antiviral therapies for serious and chronic viral diseases. Its research programs use structure-based technologies to target a range of viruses, including influenza, coronaviruses such as SARS-CoV-2 and MERS-CoV, norovirus, respiratory virus infections, and hepatitis C virus. The company’s pipeline includes CC-42344, a PB2 inhibitor in Phase 2a development for pandemic and seasonal influenza A, along with an inhaled version being studied for prophylactic use against influenza infections. Cocrystal is also advancing CDI-988, an oral pan-viral candidate in Phase 1 testing for noroviruses and coronaviruses, and CC-31244, a non-nucleoside HCV inhibitor that has completed Phase 2a trials. In addition, the company has research collaborations with Merck Sharp & Dohme and Kansas State University Research Foundation.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-COCP
|
$0.91
|
-9.2% Downside
|
Fair
|
$8
|
700.0% Upside
|
Bargain
|
Fair
|
0.0%
|
November 16, 2026
|
18.5x
|
58.4x
|
19.263 M
|
18.435 M
|
6.4%
|
61.8%
|
-108.4
|
80.2%
|
